Comera Life Sciences Holdings, Inc. – NASDAQ:CMRAW

Comera Life Sciences Holdings stock price today

$0.012
+0.01
+666.67%
Financial Health
0
1
2
3
4
5
6
7
8
9

Comera Life Sciences Holdings stock price monthly change

-65.52%
month

Comera Life Sciences Holdings stock price quarterly change

-89.95%
quarter

Comera Life Sciences Holdings key metrics

Market Cap
483.42K
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-4.53
Revenue
1.00M
EBITDA
-9.06M
Income
-84.25M
Revenue Q/Q
-41.97%
Revenue Y/Y
81.78%
Profit margin
-3467.09%
Oper. margin
-2101.96%
Gross margin
64.64%
EBIT margin
-2101.96%
EBITDA margin
-906.63%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Comera Life Sciences Holdings stock price history

Comera Life Sciences Holdings stock forecast

Comera Life Sciences Holdings financial statements

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW): Profit margin
Dec 2022 156.12K -2.91M -1867.86%
Mar 2023 392.91K -77.77M -19793.42%
Jun 2023 315.05K -1.41M -448.06%
Sep 2023 136.31K -2.15M -1580.01%
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW): Debt to assets
Dec 2022 3727113 9.97M 267.61%
Mar 2023 2999117 8.26M 275.55%
Jun 2023 2340172 8.69M 371.36%
Sep 2023 3071949 7.29M 237.39%
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW): Cash Flow
Dec 2022 -1.84M -28.57M 1.13M
Mar 2023 -1.90M -88.35K 1.58M
Jun 2023 -993.50K -5.65K -63.19K
Sep 2023 -1.91M 0 3.20M

Comera Life Sciences Holdings alternative data

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW): Employee count
Dec 2023 12
Jan 2024 12
Feb 2024 12
Mar 2024 12
Apr 2024 12
May 2024 12
Jun 2024 12
Jul 2024 12

Comera Life Sciences Holdings other data

  • What's the price of Comera Life Sciences Holdings stock today?

    One share of Comera Life Sciences Holdings stock can currently be purchased for approximately $0.01.

  • When is Comera Life Sciences Holdings's next earnings date?

    Unfortunately, Comera Life Sciences Holdings's (CMRAW) next earnings date is currently unknown.

  • Does Comera Life Sciences Holdings pay dividends?

    No, Comera Life Sciences Holdings does not pay dividends.

  • How much money does Comera Life Sciences Holdings make?

    Comera Life Sciences Holdings has a market capitalization of 483.42K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 97.95% to 633.1K US dollars.

  • What is Comera Life Sciences Holdings's stock symbol?

    Comera Life Sciences Holdings, Inc. is traded on the NASDAQ under the ticker symbol "CMRAW".

  • What is Comera Life Sciences Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Comera Life Sciences Holdings?

    Shares of Comera Life Sciences Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Comera Life Sciences Holdings have?

    As Jul 2024, Comera Life Sciences Holdings employs 12 workers.

  • What is Comera Life Sciences Holdings's official website?

    The official website for Comera Life Sciences Holdings is comeralifesciences.com.

  • Where are Comera Life Sciences Holdings's headquarters?

    Comera Life Sciences Holdings is headquartered at 12 Gill Street, Woburn, MA.

  • How can i contact Comera Life Sciences Holdings?

    Comera Life Sciences Holdings's mailing address is 12 Gill Street, Woburn, MA and company can be reached via phone at +61 78712101.

Comera Life Sciences Holdings company profile:

Comera Life Sciences Holdings, Inc.

comeralifesciences.com
Exchange:

NASDAQ

Full time employees:

12

Industry:

Biotechnology

Sector:

Healthcare

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

12 Gill Street
Woburn, MA 01801

CIK: 0001907685
:
CUSIP: 20037C116